.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Predict branded drug patent expiration
  • Uncover prior art in expired and abandoned patents

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Cipla
Boehringer Ingelheim
Dow
US Army
Chinese Patent Office
Novartis
Johnson and Johnson
Baxter
AstraZeneca
Accenture

Generated: June 25, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,743,413

« Back to Dashboard

Which drugs does patent 6,743,413 protect, and when does it expire?


Patent 6,743,413 protects FLOVENT HFA and is included in one NDA.

Protection for FLOVENT HFA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has twenty-six patent family members in twelve countries.

Summary for Patent: 6,743,413

Title: Suspension aerosol formulations
Abstract:Pharmaceutical suspension aerosol formulations containing a therapeutically effective amount of a drug and HFC 134a, HFC 227, or a mixture thereof.
Inventor(s): Schultz; Robert K. (Shoreview, MN), Schultz; David W. (Pine Springs, MN), Oliver; Martin J. (Loughborough, GB), Moris; Robert A. (Lino Lakes, MN), Jinks; Philip A. (Mount Sorrel, GB)
Assignee: 3M Company (St. Paul, MN)
Application Number:08/455,280
Patent Claim Types:
see list of patent claims
Formulation; Delivery; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Glaxo Grp Ltd
FLOVENT HFA
fluticasone propionate
AEROSOL, METERED;INHALATION021433-002May 14, 2004RXYesYes6,743,413*PED► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 6,743,413

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,101,534Suspension aerosol formulations► Subscribe
7,105,152Suspension aerosol formulations► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,743,413

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Denmark1086688► Subscribe
Denmark0717987► Subscribe
Australia1234297► Subscribe
Australia709052► Subscribe
Canada2126244► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Julphar
Covington
Dow
Federal Trade Commission
Deloitte
Fish and Richardson
Fuji
Johnson and Johnson
Mallinckrodt
Novartis

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot